Pear Therapeutics announced today that it entered into multiple agreements to bolster its prescription digital therapeutics (PDT) platform. Boston-based Pear Therapeutics’ agreements are set to add to its library of digital biomarkers, machine learning algorithms, sensor-based technologies and digital therapeutics, according to a news release. The agreements have been struck with technology companies including Empatica, […]
Pharmaceuticals
Amneal completes acquisition of Kashiv Specialty Pharmaceuticals
Amneal Pharmaceuticals (NYSE:AMRX) announced today that it completed the acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals. Bridgewater, N.J.-based Amneal develops, manufactures and distributes generic and specialty drug products. Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv BioSiences, develops complex generics, novel drugs and innovative drug delivery platforms, according to a news release. No […]
Welldoc, Dexcom expand diabetes management tech partnership
Welldoc announced today that it will offer its BlueStar digital health solution with Dexcom’s G6 CGM system as a single platform. Columbia, Md.-based Welldoc’s FDA-cleared BlueStar system offers guidance to individuals through the self-management of diabetes, while Dexcom’s G6 continuous glucose monitoring (CGM) system measures glucose levels just beneath the skin’s surface and wirelessly transmits […]
Cellphire Therapeutics closes $15M Series A
Long-term stabilization and platelet storage product developer Cellphire Therapeutics announced that it closed a $15 million Series A financing round. Rockville, Md.-based Cellphire develops Thrombosomes and Cryopreserved Platelets (CPP) in bleeding patients. The former is a platelet-based, freeze-dried hemostatic agent, while CPP — frozen platelets — is being developed for the U.S. Army to fill […]
Prescryptive to offer benefit coverage for Pear Therapeutics opioid use disorder treatments
Pear Therapeutics announced today that Prescryptive Health will offer and administer benefit coverage for its digital therapeutics. Boston-based Pear Therapeutics’ reSET and reSET-O, two FDA-cleared prescription digital therapeutics (PDTs) for treating substance and opioid use disorder, have been added to Prescryptive’s formularies and are being administered as standard pharmacy benefits for its members, according to […]
Fresenius Kabi, Corvida Medical ink U.S. distribution deal for drug-transfer device
Fresenius Kabi announced that it entered into a U.S. distribution agreement with Corvida Medical for the HALO closed system drug-transfer device (CSTD). Under the distribution agreement, Lake Zurich, Ill.-based Fresenius Kabi will be the exclusive U.S. distributor for the HALO CSTD, an airtight and leak-proof CSTD designed to prohibit the transfer of environmental contaminants into […]
FDA approves inhaled pulmonary hypertension treatment from United Therapeutics
United Therapeutics (NSDQ:UTHR) announced today that it received FDA approval for its Tyvaso inhalation solution for pulmonary hypertension. Research Triangle Park, N.C.-based United Therapeutics’ Tyvaso (treprostinil) inhalation solution is designed to treat patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability, according to a news release. With approval, Tyvaso now […]
Lyndra Therapeutics appoints Jenkins, Fernandes to executive roles
Lyndra Therapeutics announced today that it appointed Abigail Jenkins and Jacqueline Fernandes to executive positions at the company. Jenkins will take over as chief commercial & business officer, while Fernandes assumes the role of VP of data compliance and information technology at the Watertown, Mass.-based developer of oral, long-acting, sustained-release therapeutics. “We are pleased to […]
Regeneron touts results of NIH-sponsored EYLEA injection study
Regeneron Pharmaceuticals (NSDQ:REGN) announced data supporting the use of its EYLEA injection in NPDR patients. Protocol W, a NIH-sponsored trial to evaluate the EYLEA (aflibercept) injection in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR), without center-involved diabetic macular edema (CI-DME), had its initial results published in JAMA Ophthalmology. At two years, the primary […]
Pyxis Oncology closes $152M Series B
Biologics developer Pyxis Oncology announced today that it closed a Series B financing round worth $152 million. Cambridge, Mass.-based Pyxis had its financing round co-led by Arix Bioscience and RTW Investments. Existing investors including Leaps by Bayer, Longwood Fund, Agent Capital and Ipsen also contributed to the $152 million, which brings Pyxis’ total funding to […]
